Chiral Palladium NHC Complexes for Anticancer Efficacy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anticancer drugs, such as Cisplatin, face limitations including low solubility, toxicity issues, and gradual resistance from cancer cells, necessitating the development of alternative metallodrugs with enhanced therapeutic potency and selectivity.
Innovation Solution
Development of chiral palladium N-heterocyclic carbene complexes, specifically (NHC)2PdX2, where NHC is 1-(1S,2S,5R/1R,2R,5S)-menthyl-4-(R)-1,2,4-triazol-5-ylidene, with R=Et, allyl, or CH2Ph, and X=Br or OCOCF3, which exhibit high anti-cancer activity and selectivity through enhanced polar functionality and chirality.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If Cisplatin is used as an anticancer drug, then anti-cancer activity is achieved, but solubility is low and toxicity issues arise
Solution Approach 1:
The patent changes the chemical parameters of the anticancer agent by replacing platinum with palladium and introducing chiral N-heterocyclic carbene ligands with specific substituents (R=Et, allyl, CH2Ph). This parameter modification maintains anti-cancer activity while reducing toxicity through altered molecular properties and improved solubility characteristics
Solution Approach 2:
The invention creates composite metallodrug structures by combining palladium centers with chiral N-heterocyclic carbene ligands containing specific functional groups. These composite structures integrate multiple chemical features (palladium, carbene, chiral menthyl group, various R substituents) to achieve both therapeutic efficacy and reduced harmful effects
2Reliability
If Cisplatin is administered, then cancer cell proliferation is inhibited, but resistance develops gradually
Solution Approach 1:
The patent modifies the chemical parameters of the anticancer agent by using palladium instead of platinum and incorporating diverse chiral N-heterocyclic carbene ligands. These parameter changes produce novel molecular structures that interact differently with cancer cells, potentially bypassing resistance mechanisms developed against Cisplatin
Solution Approach 2:
The invention creates analogues of successful platinum-based drugs by copying the fundamental metallodrug mechanism (metal complex binding to DNA) while using palladium and chiral NHC ligands as substitutes. This copying approach with modifications aims to replicate anti-cancer efficacy while avoiding resistance issues
3Reliability
If conventional metallodrugs are used, then anti-cancer properties are achieved, but selectivity towards cancer cells is insufficient
Solution Approach 1:
The patent introduces asymmetry through chiral N-heterocyclic carbene ligands containing menthyl groups with specific stereochemistry. This asymmetric structure creates enantiomeric pairs that may interact differently with biological targets, potentially improving selectivity for cancer cells over normal cells through stereospecific recognition
Solution Approach 2:
The invention modifies local chemical properties by incorporating specific functional groups (R=Et, allyl, CH2Ph) at particular positions on the N-heterocyclic carbene ligand. These localized structural modifications create distinct molecular recognition features that may enhance selective binding to cancer cell targets
Data Source
AI summary
The present invention relates to the anticancer property studies of a series of chiral palladium N-heterocyclic carbene complexes of the general formula of (NHC)2PdX2 [NHC=chiral N-heterocyclic carbene ligand 1-(1S,2S,5R/1R,2R,5S)-menthyl-4-(R)-1,2,4-triazol-5-ylidene, wherein R=Et, allyl and CH2Ph; X═Br or OCOCF3], as designated by, (1S,2S,5R)-(1-3)b and (1R,2R,5S)-(1-3)b, (1S,2S,5R)-(1, 3)c and (1R,2R,5S)-(1, 3)c represented by formula (Ig, Ih) below.The present invention further investigates the influence of chirality on the anticancer activity, wherein the enantiomeric pairs of present chiral palladium N-heterocyclic carbene complexes of formula (Ig, Ih) shows no differential activity based on optical isomerism despite all of the palladium complexes exhibiting high anti-proliferative activity towards a variety of cancer cells. Also, provided herein is a process of preparation of the chiral palladium N-heterocyclic carbene complexes and a pharmaceutical composition comprising the chiral palladium N-heterocyclic carbene complexes. The present invention relates to the mechanistic details highlighting the mode of action of the chiral palladium N-heterocyclic carbene complex of the formulation for their anticancer application.